Journal List > J Korean Ophthalmol Soc > v.60(12) > 1139609

TOOLS
Park: Anti-Vascular Endothelial Growth Factor Therapy for Choroidal Neovascularization Secondary to Optic Nerve Head Drusen
Case Report

Journal of the Korean Ophthalmological Society 2019; 60(12): 1369-1373.

Published online: 17 December 2019

DOI: https://doi.org/10.3341/jkos.2019.60.12.1369

Anti-Vascular Endothelial Growth Factor Therapy for Choroidal Neovascularization Secondary to Optic Nerve Head Drusen

Ka Hee Park, MD

Nune Eye Hospital, Seoul, Korea.

Address reprint requests to Ka Hee Park, MD. Nune Eye Hospital, #404 Seolleung-ro, Gangnam-gu, Seoul 06198, Korea. Tel: 82-2-2086-7750, Fax: 82-2-2086-7710, ophkh@hanmail.net

Received 16 June 2019       Revised 24 October 2019       Accepted 6 December 2019

©2019 The Korean Ophthalmological Society

The Korean Ophthalmological Society

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

To describe a patient with optic nerve head drusen who showed improved retinal hemorrhage and visual acuity following intravitreal anti-vascular endothelial growth factor (bevacizumab) injection.

Case summary

A 53-year-old woman with no underlying disease presented with sudden vision loss in her left eye. Her best-corrected visual acuity was 1.0 in the right eye and 0.8 in the left eye; the intraocular pressure was 15 mmHg in both eyes. Anterior segment examination revealed no abnormal findings. Fundus examination showed subretinal hemorrhage and serous retinal detachment in the left eye. Fluorescein angiography and indocyanine green fundus examination revealed hyperfluorescence near the optic disc. The patient was diagnosed with choroidal neovascularization of the left eye secondary to optic nerve head drusen; intravitreal bevacizumab injection was then performed. Three weeks later, the patient showed improved retinal hemorrhage.

Conclusions

Intravitreal anti-vascular endothelial growth factor injection may be an effective treatment for choroidal neovascularization associated with optic nerve head drusen.

Keywords: Anti-vascular endothelial growth factor, Bevacizumab, Choroidal neovascularization, Intravitreal injection, Optic nerve head drusen

Figures and Tables

Figure 1

Visual field tests of both eyes at the first visit.

jkos-60-1369-g001
Figure 2

Fundus photography of both eyes. (A) Pre-treatment and (B) post-treatment fundus photography at 3 weeks after intravitrealbevacizumab injection.

jkos-60-1369-g002
Figure 3

Optical coherence tomography(OCT) and retinal angiograms of the lefteye. (A) A hyperreflective subretinal masslikelesion (white arrow) is buried at opticdisc and subretinal fluid extended fromthe optic nerve head to the macula andpigment epithelial detachment (blue arrow)is observed on OCT. (B) Fluoresceinand Indocyanine green angiogram revealedround small hyperfluorescencewithin the hypofluorescence area of subretinalhemorrhage.

jkos-60-1369-g003

Notes

Conflicts of Interest The authors have no conflicts to disclose.

References

1. Auw-Haedrich C, Staubach F, Witschel H. Optic disk drusen. Surv Ophthalmol. 2002; 47:515–532.
2. Palmer E, Gale J, Crowston JG, Wells AP. Optic nerve head drusen: an update. Neuroophthalmology. 2018; 42:367–384.
3. Romero J, Sowka J, Shechtman D. Hemorrhagic complications of optic disc drusen and available treatment options. Optometry. 2008; 79:496–500.
4. Kurz-Levin MM, Landau K. A comparison of imaging techniques for diagnosing drusen of the optic nerve head. Arch Ophthalmol. 1999; 117:1045–1049.
5. Lee KM, Woo SJ, Hwang JM. Differentiation of optic nerve head drusen and optic disc edema with spectral-domain optical coherence tomography. Ophthalmology. 2011; 118:971–977.
6. Seo DR, Park SH. Optical coherence tomography findings of optic nerve head drusen in children and adolescents. J Korean Ophthalmol Soc. 2015; 56:1446–1453.
7. Grippo TM, Shihadeh WA, Schargus M, et al. Optic nerve head drusen and visual field loss in normotensive and hypertensive eyes. J Glaucoma. 2008; 17:100–104.
8. Choi WG, Jang JH. A case of optic disc hemorrhage associated with buried optic disc nerve head drusen. J Korean Ophthalmol Soc. 2014; 55:1099–1105.
9. Duncan JE, Freedman SF, El-Dairi MA. The incidence of neovascular membranes and visual field defects from optic nerve head drusen in children. J AAPOS. 2016; 20:44–48.
10. Delyfer MN, Rougier MB, Fourmaux E, et al. Laser photocoagulation for choroidal neovascular membrane associated with optic disc drusen. Acta Ophthalmol Scand. 2004; 82:236–238.
11. Silva R, Torrent T, Loureiro R, et al. Bilateral CNV associated with optic nerve drusen treated with photodynamic therapy with verteporfin. Eur J Ophthalmol. 2004; 14:434–437.
12. Mateo C, Moreno JG, Lechuga M, et al. Surgical removal of peripapillary choroidal neovascularization associated with optic nerve drusen. Retina. 2004; 24:739–745.
13. Knape RM, Zavaleta EM, Clark CL 3rd, et al. Intravitreal bevacizumab treatment of bilateral peripapillary choroidal neovascularization from optic nerve head drusen. J AAPOS. 2011; 15:87–90.
14. Delas B, Almudí L, Carreras A, Asaad M. Bilateral choroidal neovascularization associated with optic nerve head drusen treated by antivascular endothelial growth factor therapy. Clin Ophthalmol. 2012; 6:225–230.
15. Saffra NA, Reinherz BJ. Peripapillary choroidal neovascularization associated with optic nerve head drusen treated with anti-VEGF agents. Case Rep Ophthalmol. 2015; 6:51–55.
TOOLS
Similar articles